安必平 (688393)
Guangzhou LBP Medicine Science and Technology Co., Ltd.
K-Line Chart
No K-line data available
Company NameGuangzhou Anbiping Medical Technology Co., Ltd.
Listing Date2020-08-20
Issue Price30.56RMB
Registered Capital9356.769910k RMB
Legal RepresentativeCai Xiangting
Registered AddressNo. 2 Kexin Street, Fengxin Road, Science City, Huangpu District, Guangzhou City, Guangdong Province
IndustryMedical Devices
Main BusinessResearch, development, production, and sales of in vitro diagnostic reagents and instruments
Company ProfileGuangzhou Anbiping Medical Technology Co., Ltd. is primarily engaged in the research, development, production, and sales of in vitro diagnostic reagents and instruments. It is a high-tech enterprise with independent R&D and innovation capabilities, and also serves as the supporting unit for the Guangdong Provincial Engineering Research Center for Pathological Diagnosis. The company has participated in multiple national major projects under the "863 Program", as well as provincial and municipal-level projects, and has obtained a total of 56 patents, including 11 invention patents. The company has established three major technology platforms: cytological diagnosis, molecular diagnosis, and immunological diagnosis. Through independent R&D and innovation, it has maturely mastered several core technologies, including sedimentation-based liquid-based cytology technology, reverse dot blot PCR preparation technology, real-time fluorescent PCR preparation technology, FISH probe synthesis and labeling technology, IHC pathological diagnostic antibody screening and quality control technology, related supporting instrument manufacturing technology, and "RealVision"—a cloud-based real-time remote pathological collaboration technology. Based on these, the company has established corresponding product lines. Currently, the company has 485 registered/filed products, and the number is continuously increasing, meeting the needs of medical institutions at different levels. Leveraging the synergistic advantages of its self-branded reagents and instruments, a comprehensive marketing network, and a high-quality after-sales service system, the company's products have covered nearly 1,800 medical institutions nationwide.
Stock Details
1. Key Indicators
- Total Shares(W): 9356.77
- Circulating A-Shares(W): 7870.49
- Earnings Per Share(RMB): -0.1200
- Net Assets Per Share(RMB): 13.1021
- Operating Revenue(W RMB): 25292.01
- Total Profit(W RMB): -1741.11
- **Net Profit Attributable to Parent(W RMB) **: -1076.71
- Net Profit Growth Rate(%): -136.34
- Weighted Return on Equity(%): -0.8600
- Operating Cash Flow Per Share(RMB): 0.4130
- Undistributed Profit Per Share(RMB): 3.8608
- Capital Reserve Per Share(RMB): 7.7424
2. Main Business
The main business covers:
- Research, development, production, and sales of in vitro diagnostic reagents and instruments
3. Company Basic Information
- Company Name: Guangzhou Anbiping Pharmaceutical Technology Co., Ltd.
- Listing Date: 2020-08-20
- Industry: Pharmaceutical Manufacturing
- Address: No. 2 Kexin Street, Fengxin Road, Science City, Huangpu District, Guangzhou City, Guangdong Province
- Website: https://www.gzlbp.com
- Company Profile: Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. was established through the overall transformation of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. On February 28, 2014, all the company's promoters signed the "Promoter Agreement," stipulating that the company would be transformed into a joint stock company based on the audited net assets of the limited company as of December 31, 2013. The share capital of the joint stock company was 70 million yuan, with the remaining 134.8726 million yuan included in the capital reserve. The rights and obligations of each promoter during the establishment of the joint stock company were also clarified. On February 27, 2014, ShineWing Certified Public Accountants (Special General Partnership) issued the "Capital Verification Report" numbered "XYZH/2012GZA1103-1," verifying that as of December 31, 2013, Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. (in preparation) had received paid-in capital of 70 million yuan from all contributors in the form of the company's net assets. On March 24, 2014, Anbiping completed the industrial and commercial registration with the Guangzhou Administration for Industry and Commerce and obtained the "Business License of Enterprise Legal Person" with registration number 440108000003389.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Guangzhou Kaiduo Investment Consulting Center (Limited Partnership) | Corporate Entity | 1295.14 | 16.46 |
| 2 | Zhuji Gaotejia Ruian Investment Partnership (Limited Partnership) | Corporate Entity | 359.67 | 4.57 |
| 3 | Guangzhou Da'an Gene Technology Co., Ltd. | Corporate Entity | 348.60 | 4.43 |
| 4 | Nanjing Qianjing Venture Capital Partnership (Limited Partnership) | Corporate Entity | 167.73 | 2.13 |
| 5 | Chongqing Gaotejia Ruian Equity Investment Fund Partnership (Limited Partnership) | Corporate Entity | 134.35 | 1.71 |
| 6 | Great Wall Consumption Value-Added Mixed Securities Investment Fund Class A | Fund | 85.00 | 1.08 |
| 7 | Hangzhou Gaotejia Ruihai Investment Partnership (Limited Partnership) | Corporate Entity | 82.63 | 1.05 |
5. Concept Sectors
- Gene Concept
- Smart Healthcare
- Artificial Intelligence
- Tencent Concept
- Hepatitis Concept
- Huawei Computing Power
- AI Healthcare
- Margin Trading & Securities Lending
- Micro-cap Stocks
- Below IPO Price
- Planned Reduction
Remarks
- Data update date: 2025-11-05
- Data source: Public Market Information